Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT01646840
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Test productDrug: Reference product
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT01632449
- Locations
- 🇺🇸
Research Site, Minneapolis, Minnesota, United States
Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers
- Conditions
- HealthyMultiple Sclerosis
- Interventions
- Device: BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)Device: BIIB017 (peginterferon beta-1a) Autoinjector
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 55
- Registration Number
- NCT01610310
- Locations
- 🇺🇸
Research Site, St. Paul, Minnesota, United States
Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: BIIB041 (PR Fampridine)Other: Placebo
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 132
- Registration Number
- NCT01597297
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 173
- Registration Number
- NCT01568112
- Locations
- 🇺🇸
Research Site, St Paul, Minnesota, United States
Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 82
- Registration Number
- NCT01561027
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
- Conditions
- Multiple Sclerosis
- Interventions
- Other: clinical and neurological evaluationGenetic: Blood Sample
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT01556685
- Locations
- 🇲🇽
Research Site, Leon, Guanajuato, Mexico
A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 67
- Registration Number
- NCT01540630
- Locations
- 🇬🇧
Professor Joanna Zakrzewska, London, United Kingdom
Fampridine Pregnancy Exposure Registry
- Conditions
- Multiple SclerosisPregnancy
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1
- Registration Number
- NCT01532154
- Locations
- 🇫🇷
Hopital Pitie Salpetriere, Paris, France
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT01518894
- Locations
- 🇺🇸
Pfizer Investigational Site, Long Beach, California, United States